Eversept Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Eversept Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-128,905	Closed	-$3.27M	–	75
2020 Q2	$3.27M	Buy	128,905 +69,131	+116%	+$1.49M	0.45%	36
2020 Q1	$1.1M	Buy	59,774 +41,100	+220%	+$799K	0.27%	42
2019 Q4	$411K	Sell	18,674 -22,400	-55%	-$451K	0.07%	70
2019 Q3	$590K	Hold	41,074	–	–	0.18%	50
2019 Q2	$647K	Hold	41,074	–	–	0.18%	52
2019 Q1	$602K	Hold	41,074	–	–	0.18%	43
2018 Q4	$439K	Sell	41,074 -10,000	-20%	-$132K	0.24%	45
2018 Q3	$779K	Sell	51,074 -33,926	-40%	-$494K	0.34%	41
2018 Q2	$1.04M	Buy	+85,000	New	+$1.07M	0.48%	43

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Eversept Partners's DRNA Position: Q3 2020 in Review

Eversept Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 128,905 shares — an estimated $3.27M sold.

Eversept Partners first reported a position in DRNA in Q2 2018 and held it in 9 quarters. The position peaked at $3.27M in Q2 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

Eversept Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Eversept Partners sold 128,905 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $3.27M.
Eversept Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 9 quarters.
Eversept Partners's Dicerna Pharmaceuticals, Inc. position peaked at $3.27M in Q2 2020.
172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.